High-Resolution AAV Capsid Characterization Service
Introduction
Partnered with NanoEngineering Corporation, our High-Resolution AAV Capsid Characterization Service leverages the NanoRanger™ ES-DMA aerophoresis platform combined with CD-MS. It delivers angstrom-scale resolution to quantify empty, partial, full, and overfilled rAAV capsids through linear mass-mobility correlation.
Requiring only micro-volume samples, the validated workflow generates regulatory-compliant quantitative CQA data across full R&D and manufacturing stages, resolving subtle capsid heterogeneity and accelerating gene therapy QC testing.
Discover How We Can Help - Request a Consultation
High-Resolution AAV Capsid Characterization Service
WHY ES-DMA?
AAV mixtures of empty, partial, full, and overfilled capsids lead to batch loss and regulatory risks, with standard assays lacking balanced resolution, speed, and cost. NanoRanger™ ES-DMA aerophoresis separates intact AAV via DuoPole™ ionization. Its linear size-DNA correlation quantifies all four capsid groups in one scan as a low-cost substitute for complex analytical tools.
Service Recipients
| Process Development scientists | Analytical & QC directors | CDMOs and contract testing labs | Academic AAV researchers |
|---|---|---|---|
| Characterize complex upstream samples that conventional assays can't access. | Add a high-resolution orthogonal method to de-risk lot release and comparability. | Differentiate your service menu with a novel method outside the standard AUC/CD-MS QC workflow. | Ensure consistent dosing, reduce variability, and generate publication-quality results. |
Application Scenarios
- Process Development: Characterize crude lysates and purified fractions to optimize upstream and downstream workflows.
- Quality Control: Conduct batch release testing, sample comparability assessment, and in-line process monitoring.
- Academic Research: Explore the packaging mechanism of viral vectors and generate high-precision quantitative data for publications.
- CDMO Contract Testing Services: Expand service portfolios by providing orthogonal analytical methods beyond standard AUC and CD-MS workflows.
Workflow
Our efficient analytical workflow boosts throughput without compromising precision. Integrating fast sample preparation and gas-phase mobility detection, this benchtop method acts as a reliable orthogonal substitute for conventional AUC.
Required Starting Materials
To initiate the high-resolution characterization service, clients typically provide:
-
Purified rAAV Samples:
- Minimum volume per aliquot: ≈ 10 μL
- Concentration requirement: ≥ 1 × 1011 vg/mL (viral genomes per milliliter)
- Suggested buffer: Low-salt volatile buffer
- Vector Genetic Information: Detailed construct details (e.g., target single-stranded or self-complementary DNA sequence maps, promoter specifications, and expected transgene size in base pairs).
- Historical Reference Profiles: Pre-existing sizing data or formulation parameters, such as dynamic light scattering (DLS) or high-performance liquid chromatography (HPLC) profiles, if available.
Key Steps Involved
- Sample Quality Inspection & Volatile Buffer Exchange
- Electrospray Ionization (ESI) and Aerosolization
- Gas-Phase Electrical Mobility Classification (ES-DMA)
- High-Resolution Particle Sizing and Mass Mapping
- Data Deconvolution and Quantitative Assessment
Final Deliverables
- Interactive high-resolution particle size distribution spectrum, marking precise electrical mobility diameters at the angstrom scale
- Quantitative table calculating percentage ratios of empty, partially filled, and full AAV capsids.
- Official analytical report covering experimental parameters, instrument calibration curves, viral concentration (≥ 109) particles/mL, and cross-reference data against CD-MS reference results
Estimated Timeframe
The typical timeframe for this analytical service ranges from 2 to 4 weeks. The precise duration is influenced by factors such as the specific AAV serotype (e.g., AAV2, AAV5, AAV8, AAV9), the complexity of the encapsidated transgene, sample purity, and the total volume of concurrent samples submitted for analysis.
What We Can Offer
To support the diverse and evolving pipelines of our global biopharmaceutical partners, Creative Biolabs provides a highly flexible and comprehensive suite of capabilities designed to overcome traditional characterization bottlenecks.
Balanced Comprehensive Performance
Solves the common dilemma of conventional AUC and CD-MS that fail to deliver optimal resolution, throughput, and cost-effectiveness simultaneously.
Sample-Friendly Operation
Only 1-5 μL micro-volume samples are required; sample preparation merely involves buffer exchange or dilution with minimal sample loss.
Cost and Time Efficiency
Each sample test takes little time, while the purchase and maintenance costs of the instrument are far lower than comparable high-end analytical devices.
Authoritative Data Output
Test results show strong consistency with AUC, CD-MS, and mass photometry, and the related methodology has been submitted to Nature Gene Therapy.
Regulatory Compliance Support
Generated data can be applied to process development, comparability studies, and commercial batch release to mitigate regulatory risks.
Experience the Creative Biolabs Advantage - Get a Quote Today
Case Study
| Strong concordance with CD-MS and AUC | |
|---|---|
|
|
| High sensitivity quantification of empty /partial /overfill ratios | |
|
|
| Detect and quantify higher-order aggregation states. | |
|
|
FAQs
How does ES-DMA compare to Analytical Ultracentrifugation (AUC) for assessing empty/full capsid ratios?
AUC demands large sample volumes, long testing periods, and complicated data processing. Our ES-DMA service delivers angstrom-level resolution with merely ~10 μL samples. It separates particles by gas-phase electrical mobility, providing a fast, stable benchtop method for cross-verification.
What is the limit of detection (LOD) and dynamic range for the characterization service?
The LOD for intact virions reaches 109 particles/mL. The platform maintains linearity across nearly three orders of magnitude, supporting accurate detection of both high-concentration finished products and low-titer early research samples.
Can this service differentiate between overfilled, full, and partially filled capsids?
Yes. ES-DMA's ultrahigh resolution links mobility to particle mass, generating separate peaks for empty, partially loaded, fully packaged, and overfilled capsids. Each genome loading subgroup can be quantified precisely.
Are there any specific buffer precautions or sample preparations we need to perform?
High non-volatile salt, surfactant, or glycerol content disturbs electrospray and broadens peaks. We automatically conduct a micro buffer exchange to volatile ammonium acetate upon sample receipt to reduce your manual preparation work.
Is this characterization platform compatible with all AAV serotypes and novel synthetic capsids?
Yes. ES-DMA detects the ~25 nm physical diameter of AAV capsids, independent of serotype differences. It accurately analyzes conventional AAV1-AAV9, chimeric mutants, and artificially designed capsids.
Related Sections
Creative Biolabs offers advanced High-Resolution AAV Capsid Characterization for gene therapy programs. We deliver accurate capsid packaging ratios and regulatory-compliant QC data. Our expert biophysicists support projects from early capsid design to final batch testing to guarantee therapeutic safety and potency.
Contact Our Team for More Information and to Discuss Your Project
